Mirikizumab-Mrkz vs Risankizumab-Rzaa — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Interleukin-23 Antagonist

Mirikizumab-Mrkz

Brand: Omvoh

First FDA approval: 2023-10-26

Interleukin-23 Antagonist

Risankizumab-Rzaa

Brand: Skyrizi

First FDA approval: 2021-04-26

Lowest NADACAcquisition cost floor across all NDCs

—Per unit

$9679.49Per unit

Average NADACAcross all dosage forms and strengths

—

$18476.52Up to $22942.37

Generic manufacturersActive ANDA holders — FDA Orange Book

00 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$11.0MFull year

$4.58BFull year

Part D claims (CY24)Total fills, all strengths

995263 beneficiaries

218K84K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$11,025Per claim, all NDCs

$21,034Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

6Minimal friction

1212Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

DiscontinuedSee drug profile

NoneClear

Generic availableFDA Orange Book

NoBrand-only